Barr, Galen contraceptive deals

BRL signed a letter of intent to acquire exclusive rights from Galen (LSE:GAL; GALN) to Loestrin and Loestrin FE oral contraceptives in the U.S. and Canada. The companies also proposed to settle their pending litigation related to GAL's femhrt hormone therapy and Estrostep oral contraceptive. The settlement would allow BRL to launch generic versions of the products six months prior to patent expiration. In exchange, BRL would make a one-time $45 million payment to GAL. ...